Vistagen reports new preclinical data supporting itruvone (ph10) nasal spray's potential antidepressant activity via peripheral nasal neurons without entry into the brain

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats. the study demonstrated that a single intranasal administration of radiolabeled itruvone ([14c]ph10) was essentially undetectable.
VTGN Ratings Summary
VTGN Quant Ranking